Despite the impressive clinical impact of programmed death-ligand 1 (PD-L1)/programmed cell death-1 (PD-1) blockade in solid tumors, the use of these checkpoint inhibitors in multiple myeloma (MM) still remains debated with unsatisfying clinically meaningful results. This evidence concerns the gene CD274 and plasma cell myeloma.